Treatment of Non-Neurogenic Overactive Bladder – American Urological Association and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline Overview

1. Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29(1): 4–20. doi: 10.1002/nau.20798.

2. Gormley EA, Lightner DJ, Burgio KL et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188(6): 2455–2463. doi: 10.1016/j.juro.2012.09.079.

3. Fitzgerald MP, Brubaker L. Variability of 24-hour voiding diary variables among asymptomatic women. J Urol 2003; 169(1): 207–209.

4. Gormley EA, Lightner DJ, Faraday M et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193(5): 1572–1580. doi: 10.1016/j.juro.2015.01.087.

5. Fantl JA, Wyman JF, McClish DK et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991; 265(5): 609–613.

6. Jarvis GJ. A controlled trial of bladder drill and drug therapy in the management of detrusor instability. BJU Int 1981; 53(6): 565–566.

7. Burgio KL, Locher JL, Goode PS et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998; 280(23): 1995–2000.

8. Burgio KL, Goode PS, Johnson TM et al. Behavioral versus drug treatment for overactive bladder in men: the male overactive bladder treat­ment in veterans (MOTIVE) trial. J Am Geriatr Soc 2011; 59(12): 2209–2216. doi: 10.1111/j.1532-5415.2011.03724.x.

9. Goode PS, Burgio KL, Locher JL et al. Urodynamic changes associated with behavioral and drug treat­ment of urge incontinence in older women. J Am Geriatr Soc 2002; 50(5): 808–816.

10. Kaya S, Akbayrak T, Beksac S. Comparison of dif­ferent treatment protocols in the treatment of idio­pathic detrusor overactivity: a randomized con­trolled trial. Clin Rehabil 2011; 25(4): 327–338. doi: 10.1177/0269215510385481.

11. Subak LL, Wing R, West DS et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009; 360(5): 481–490. doi: 10.1056/NEJMoa0806375.

12. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008; 102(1): 62–66. doi: 10.1111/j.1464-410X.2008.07463.x.

13. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002; 11(8): 560–565.

14. Burgio KL, Goode PS, Locher JL et al. Behavioral training with and without biofeedback in the treat­ment of urge incontinence in older women: a randomized controlled trial. JAMA 2002; 288(18): 2293–2299.

15. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and elec­trical stimulation in the management of overactive bladder. Urology 2004; 63(1): 61–66.

16. Cartwright R, Srikrishna S, Cardozo L et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-bind trial of transdermal oxybutynin for the treatment of urgency and urgent incontinence. BJU Int 2010; 107(1): 70–76. doi: 10.1111/j.1464-410X.2010.09591.x.

17. Nitti, VW, Khullar V, van Kerrebroeck P et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomized, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013; 67(7): 619–632. doi: 10.1111/ijcp.12194.

18. Herschorn S, Barkin J, Castro-Diaz D et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of over­active bladder. Urology 2013; 82(2): 313–320. doi: 10.1016/j.urology.2013.02.077.

19. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173(2): 493–498.

20. Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50(2): 317–326.

21. Cui Y, Wang L, Liu L et al. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int 2013; 91(4): 429–438. doi: 10.1159/000351037.

22. Dmochowski R, Chapple C, Nitti V et al. Efficacy and safety of onabotulinumtoxin A for idiopathic over­active bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184(6): 2416–2422. doi: 10.1016/j.juro.2010.08.021.

23. Kuo, HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007; 178(1): 1359–1363.

24. Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180(1): 217–222. doi: 10.1016/j.juro.2008.03.028.

25. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor over­activity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177(6): 2231–2236.

26. Jeffery S, Fynes M, Lee F et al. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Intl 2007; 100(6): 1302–1306.

27. Kessler TM, Danuser H, Schumacher M et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24(3): 231–236.

28. Kessler TM, Khan S, Panicker J et al. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009; 113(5): 1046–1051. doi: 10.1097/AOG.0b013e3181a1f5ea.

29. Khan S, Kessler TM, Apostolidis A et al. What a patient with refractory idiopathic detrusor over­activity should know about botulinum neurotoxin type A injection. J Urol 2009; 181(4): 1773–1778. doi: 10.1016/j.juro.2008.11.110.

30. Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxin A injection in pa­tients with refractory detrusor overactivity. Neurourol Urodyn 2014; 33(8): 1235–1239. doi: 10.1002/nau.22494.

31. Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term suc­cess rate after intravesical onabotulinumtoxin A injection for refractory idiopathic detrusor overactivity. J Urol 2013; 189(5): 1804–1810. doi: 10.1016/j.juro.2012.11.089.

32. Dowson C, Watkins J, Khan MS et al. Repeated botulinum toxin type A injections for refractory over­active bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012; 61(4): 834–839. doi: 10.1016/j.eururo.2011.12.011.

33. Veeratterapillay R, Harding C, Teo L et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol 2014; 21(2): 175–178. doi: 10.1111/iju.12205.

34. Mohee A, Khan A, Harris N et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013; 111(1): 8. doi: 10.1111/j.1464-410X.2012.11285.x.

35. Hegele A, Frohme C, Varga Z et al. Antibodies ­after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance. Urol Int 2011; 87(4): 439–444. doi: 10.1159/000332194.

36. Klingler HC, Pycha A, Schmidbauer J et al. Use of peripheral neuromodulation of the S3 region for treat­ment of detrusor overactivity: a urodynamic--based study. Urology 2000; 56(5): 766–771.

37. MacDiarmid SA, Peters KM, Shobeiri SA et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010; 183(1): 234–240. doi: 10.1016/j.juro.2009.08.160.

38. Peters KM, Carrico DJ, Perez-Marrero RA et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT ­trial. J Urol 2010; 183(4): 1438–1443. doi: 10.1016/j.juro.2009.12.036.

39. Marchal C, Herrera B, Antuna, F et al. Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started? Urology 2011; 78(5): 1046–1050. doi: 10.1016/j.urology.2011.07.1394.

40. Peters KM, Shen L, McGuire M. Effect of sac­ral neuromodulation rate on overactive bladder symp­toms: a randomized crossover feasibility study. LUTS 2013; 5(3): 129–133.

41. Yoong W, Shah P, Dadswell R et al. Sustained effectiveness of percutaneous tibial nerve stimula­tion for overactive bladder syndrome: 2-year follow-up of positive responders. Int Urogynecol J 2013; 24(5): 795–799. doi: 10.1007/s00192-012-1936-3.

42. Peters KM, MacDiarmid SA, Wooldridge LS et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182(3): 1055–1061. doi: 10.1016/j.juro.2009.05.045.

43. Sancaktar M, Ceyhan ST, Akyol I et al. The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic ther­apy in women with severe overactive bladder. Gynecol Endocrinol 2010; 26(10): 729–732. doi: 10.3109/09513591003649815.

44. Souto SC, Reis LO, Palma T et al. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with over­active bladder syndrome. World J Urol 2013; 32(1): 179–184. doi: 10.1007/s00345-013-1112-5.

45. Gaziev G, Topazio L, Iacovelli V et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treat­ment of lower urinary tract dysfunctions: a systematic review. BMC Urol 2013; 13: 61–72. doi: 10.1186/1471-2490-13-61.

46. Moossdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimula­tion on adult patients with overactive bladder syn­drome: a systematic review. Neurourol Urodyn 2013: 32(3): 206–214. doi: 10.1002/nau.22296.

47. Siegel S, Noblett K, Mangel J et al. Results of a prospective, randomized, multicenter study evaluat­ing sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn 2015; 34(3): 224–230. doi: 10.1002/nau.22544.

48. Angioli R, Montera R, Plotti F et al. Success ­rates, quality of life, and feasibility of sacral nerve stimula­tion in elderly patients: 1-year follow-up. Int Urogynecol J 2013; 24(5): 789–794. doi: 10.1007/s00192-012-1928-3.

49. Faucheron JL, Chodez M, Boillot B. Neuro­modulation for fecal and urinary incontinence: functional results in 57 consecutive pa­tients from a single institution. Dis Colon Rectum 2012; 55(12): 1278–1283. doi: 10.1097/DCR.0b013e31826c7789.

50. Smits MA, Oerlemans D, Marcelissen TA et al. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin ther­apy. J Urol 2013; 190(6): 2148–2152. doi: 10.1016/j.juro.2013.07.017.

51. Leong RK, Marcelissen TA, Nieman FH et al. Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey. J Urol 2011; 185(2): 588–592. doi: 10.1016/j.juro.2010.09.090.

52. Sutherland SE, Lavers A, Carlson A et al. Sacral nerve stimulation for voiding dysfunction: one institution’s 11-year experience. Neurourol Urodyn 2007; 26(1): 19–28.

53. Oerlemans DJ, Van Voskuilen AC, Marce­lissen T et al. Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime? Neurourol Urodyn 2011; 30(8): 1493–1496. doi: 10.1002/nau.21070.